Breakthroughs in Alzheimer's Treatment: Weekly Leqembi Update

Alzheimer’s Treatment Briefing

Coverage period: January 20–26, 2026 (United States)

Below are the most meaningful, truly new developments from the past 7 days, ranked by impact on treatment and access.

  1. FDA puts at‑home, weekly Leqembi injections on Priority Review
  • Overview
    • On January 25, the FDA accepted Eisai/Biogen’s application and granted Priority Review for LEQEMBI IQLIK (autoinjector) as a weekly starting dose, setting a target decision date of May 24, 2026. If approved, people could begin therapy at home (not just switch to injections after IV), using two quick 250 mg injections per week. This would be the first anti‑amyloid therapy offering both at‑home initiation and maintenance. (biospace.com)
  • Why this matters
    • Easier starts mean more eligible patients can actually begin treatment. Moving initiation from infusion centers to the home could cut wait lists, reduce travel, and free scarce MRI/infusion capacity for safety monitoring and other care. It also reduces staffing and chair‑time pressures that have slowed rollout. (biospace.com)
  1. Medicare operational update that helps home specimen collection (supports blood‑based triage)
  • Overview
    • CMS’ January 15 MLN Connects notice includes 2026 updates on travel allowance fees for specimen collection and a shift to electronic CLIA certificates by March 1, 2026. These administrative tweaks affect how labs and mobile phlebotomy services bill and operate. (cms.gov)
  • Why this matters
    • Blood tests are increasingly used to confirm Alzheimer’s‑type brain changes and to triage who should be evaluated for drugs like lecanemab or donanemab. Clearer billing rules and fully electronic lab certification make it easier for systems to stand up home or community collection—especially important for rural patients and those with mobility limits. (cms.gov)
  1. JAMA editors spotlight Alzheimer’s blood biomarkers this week
  • Overview
    • JAMA’s January 23 Editor’s Summary highlighted “Biomarkers for Alzheimer Disease,” reflecting how fast these tests are moving into everyday practice discussions. While not a new trial, it’s a signpost that top journals see immediate clinical relevance. (jamanetwork.com)
  • Why this matters
    • Clinical culture shifts matter. When general medical journals elevate a topic, primary‑care and hospital teams engage sooner—accelerating adoption of blood‑based triage that can route the right patients to treatment evaluation faster. (jamanetwork.com)
  1. Near‑term pipeline: Tau‑focused meeting pushes next‑gen (add‑on/combo) strategies
  • Overview
    • The Alzheimer’s Association announced the Tau Global Conference (May 14–15, 2026; abstracts due February 18/23). Expect data on tau‑targeting drugs and biomarkers—key pieces for pairing with anti‑amyloid antibodies. (alz.org)
  • Why this matters
    • Today’s drugs mainly clear amyloid. Many researchers expect better results by also targeting tau. This meeting is a near‑term venue likely to surface combination or step‑therapy ideas that could translate into trial designs and, eventually, care pathways. (alz.org)

What this means for care right now

  • Prepare for home initiation workflows
    • If FDA approves weekly at‑home autoinjector starts, clinics should map new patient flows: training for self‑injection, early‑phase MRI scheduling, ARIA safety protocols, and coordination with specialty pharmacies for timely delivery. (biospace.com)
  • Expand blood‑first triage, including home collection
    • Use blood biomarkers to decide who needs imaging and treatment consults. Leverage CMS’ 2026 administrative updates to support mobile/home collection and smoother lab operations. (cms.gov)
  • Watch the tau space
    • Track announcements around the Tau Global Conference for add‑on therapies that could be layered with amyloid‑clearing drugs to preserve daily function longer. (alz.org)

Sources

  • FDA Priority Review for at‑home weekly autoinjector initiation (LEQEMBI IQLIK): January 25–26, 2026 reports. (biospace.com)
  • CMS MLN Connects (January 15, 2026): specimen collection travel allowance update; electronic CLIA certificates by March 1, 2026. (cms.gov)
  • JAMA Editor’s Audio Highlights (week of January 17–23, 2026): biomarker focus. (jamanetwork.com)
  • Tau Global Conference 2026 details and deadlines (posted January 2026). (alz.org)

If a week brings no other truly new, treatment‑relevant developments, I will keep sections short rather than repeat prior items.